Diarrhea
Conditions
Keywords
probiotics, children
Brief summary
This Study based on the actual clinical diagnosis and treatment of data, evaluate the clinical characteristics of children with diarrhea Therapeutic effect and security, and establish the platform to childhood diarrhea registration, long-term accumulation of clinical data, develop the clinical characteristics and therapeutic effect of childhood diarrhea, safety monitoring data, and provide reliable data support for the clinical application.
Detailed description
To evaluate the causes, clinical manifestations, treatment plans and clinical outcomes of diarrhoeal disease in children in a real diagnosis and treatment setting。 Evaluate the effect of different treatment schemes in actual clinical application,the clinical use of nutrition-supported zinc in oral rehydration fluids,the influencing factors of clinical efficacy, including the demographic characteristics and clinical characteristics of the children, as well as drug combination regimens, etc. To evaluate the clinical use of antibiotics,the clinical effects of different probiotics in the treatment of diarrhoeal disease in children,the effectiveness, safety and economy of the dose course of the clinical application of Clostridium butyricum bivariate living agents, the medical costs and resource consumption of treatment for diarrhoeal diseases in children.
Interventions
OTHERregisty
Children with diarrhea were registered in the hospital. Baseline information of the children was recorded and followed up to observe the distribution of disease types, clinical manifestations, treatment plans and clinical outcomes
Sponsors
Zhejiang University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Under the age of 18 * Children diagnosed with diarrhea, including: 1. Acute diarrhea: infectious, such as viral bacteria, and non-infectious, such as improper diet and climate factors 2. Persistent chronic diarrhea: Including the following diseases: 1. Food allergy, food intolerance, indigestion, etc.; 2. Inflammatory bowel disease (IBD); 3. Diarrhoeal irritable bowel syndrome; 4. Antibiotic associated diarrhea (AAD); 5. Others: chronic hepatitis associated diarrhea, metabolic diseases associated diarrhea (such as diabetes mellitus with diarrhea), pancreatic exocrine dysfunction (cystic fibrosis), etc 3. Volunteered to participate in this study and signed the informed consent or the guardian signed the informed consent
Exclusion criteria
1. Class A infectious diseases associated with diarrhoea (cholera, plague) 2. Children with congenital heart disease, immune deficiency, malformation of digestive tract, or with severe dysfunction of heart, lung, liver and kidney。 3. Children receiving long-term immunosuppressive therapy (except children with IBD)。 4. Children with gastrointestinal surgery and tumor; 5. In addition to the above, the researchers determined that there were other children who were not suitable to participate in the study。
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical outcomes of diarrhoeal disease in children | acute diarrhea up to 14 days；persistent diarrhea and chronic diarrhea up to 28 days | symptom remission rate of children with diarrhoea |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Influencing factors of clinical outcomes | acute diarrhea up to 14 days；persistent diarrhea and chronic diarrhea up to 28 days | — |
| Direct medical costs | acute diarrhea up to 14 days；persistent diarrhea and chronic diarrhea up to 28 days | including drugs, laboratory tests, treatment, emergency care, and other (all-cause) medical expenses |
| effectiveness of combined clostridium butyricum and bifidobacterium powders | acute diarrhea up to 14 days；persistent diarrhea and chronic diarrhea up to 28 days | Change from baseline in stool consistency during the period of observation |
| safety evaluation | acute diarrhea up to 14 days；persistent diarrhea and chronic diarrhea up to 28 days | The proportion of Adverse events and serious adverse events |
Countries
China
Outcome results
None listed